Showing results (2051-2060 of 3,978) with videos related to

Sort By:
Pageof 398
European Journal of Heart Failure|November 27, 2021
Changes in inferior vena cava area represent a more sensitive metric than changes in filling pressures during experimental manipulation of intravascular volume and toneJuan B Ivey-Miranda, Friedrich Wetterling, Robert Gaul, et al.
European Journal of Heart Failure|February 22, 2019
Rationale and design of the European multicentre study on Stem Cell therapy in IschEmic Non-treatable Cardiac diseasE (SCIENCE)Christina Paitazoglou, Martin W Bergmann, Bojan Vrtovec, et al.
European Journal of Heart Failure|February 22, 2019
High risk of heart failure associated with desmoglein-2 mutations compared to plakophilin-2 mutations in arrhythmogenic right ventricular cardiomyopathy/dysplasiaAlexis Hermida, Véronique Fressart, Francoise Hidden-Lucet, et al.
European Journal of Heart Failure|August 14, 2019
Why has positive inotropy failed in chronic heart failure? Lessons from prior inotrope trialsTariq Ahmad, P Elliott Miller, Megan McCullough, et al.
European Journal of Heart Failure|February 2, 2021
Use of biomarkers to diagnose and manage cardiac amyloidosisVincenzo Castiglione, Maria Franzini, Alberto Aimo, et al.
European Journal of Heart Failure|January 15, 2021
Prevention of heart failure events with intensive versus standard blood pressure lowering across the spectrum of kidney function and albuminuria: a SPRINT substudyMuthiah Vaduganathan, Manan Pareek, Anna M D Kristensen, et al.
European Journal of Heart Failure|March 1, 2014
Incident heart failure in relation to vascular disease: insights from the Health, Aging, and Body Composition StudyHassan Khan, Andreas P Kalogeropoulos, Faiez Zannad, et al.
European Journal of Heart Failure|March 1, 2014
Prognosis and response to therapy of first inpatient and outpatient heart failure event in a heart failure clinical trial: MADIT-CRTHicham Skali, Edward M Dwyer, Robert Goldstein, et al.
European Journal of Heart Failure|October 10, 2009
Serum levels of large tenascin-C variants, matrix metalloproteinase-9, and tissue inhibitors of matrix metalloproteinases in concentric versus eccentric left ventricular hypertrophyMarcus Franz, Alexander Berndt, Annelore Altendorf-Hofmann, et al.
European Journal of Heart Failure|March 22, 2019
A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)John J V McMurray, David L DeMets, Silvio E Inzucchi, et al.
Pageof 398